Optimal use of recombinant granulocyte colony-stimulating factor with chemotherapy for solid tumors

References

• Fortner BV, Tauer K, Zhu L et al. Medical visits for chemotherapy and chemotherapy-induced neutropenia: a survey of the impact on patient time and activities. BMC Cancer4, 22 (2004).
   PubMed Web of Science ®Google Scholar
• Caggiano V, Weiss RV, Rickert TS, Linde-Zwirble WT. Incidence, cost and mortality of neutropenia hospitalization associated with chemotherapy. Cancer103, 1916–1924 (2005).
   PubMed Web of Science ®Google Scholar
• Courtney DM, Aldeen AZ, Gorman SM et al. Cancer-associated neutropenic fever: clinical outcome and economic costs of emergency department care. Oncologist12, 1019–1026 (2007).
   PubMed Web of Science ®Google Scholar
• Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer106(10), 2258–2266 (2006).
   PubMed Web of Science ®Google Scholar
• Elting LS, Lu C, Escalante CP et al. Outcomes and cost of outpatient or inpatient management of 712 patients with febrile neutropenia. J. Clin. Oncol.26, 606–611 (2008).
   PubMed Web of Science ®Google Scholar
• Cameron D. Management of chemotherapy-associated febrile neutropenia. Br. J. Cancer101(Suppl.), S18–S22 (2009).
   PubMed Web of Science ®Google Scholar
• Even C, Taillade L, Spano JP, Vignot S. Febrile neutropenia in adult patients with solid tumors: a review of literature toward a rationale and optimal management. Bull. Cancer97, 547–557 (2010).
   Google Scholar
• Herbst C, Naumann F, Kruse EB et al. Prophylactic antibiotics or G-CSF for the prevention of infections and improvement of survival in cancer patients undergoing chemotherapy. Cochrane Database Syst. Rev.21, CD007107 (2009).
   Google Scholar
• Walwyn M, Nicholson A, Lee MG, Wharfe G, Frankson MA. Febrile neutropenia in cancer patients. West. Indian Med.59, 209–214 (2010).
   PubMed Web of Science ®Google Scholar
• Aapro MS, Cameron DA, Pettengell R et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur. J. Cancer42(15), 2433–2453 (2006).
   PubMed Web of Science ®Google Scholar
• Citron ML, Berry DA, Cirrincione C et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J. Clin. Oncol.21(8), 1431–1439 (2003).
   PubMed Web of Science ®Google Scholar
• Marangolo M, Bengala C, Conte PF et al. Dose and outcome: the hurdle of neutropenia (review). Oncol. Rep.16(2), 233–248 (2006).
   Google Scholar
• Crawford J, Armitage J, Balducci L et al. Myeloid growth factors. J. Natl. Compr. Canc. Netw.7, 64–83 (2009).
   Google Scholar
• Teuffel O, Ethier MC, Alibhai SM, Beyene J, Sung L. Outpatient management of cancer patients with febrile neutropenia: a systematic review and meta-analysis. Ann. Oncol. DOI: 10.1093/annonc/mdq745 (2011) (Epub ahead of print).
   Google Scholar
• Clark OA, Lyman GH, Castro AA, Clark LG, Djulbegovic B. Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J. Clin. Oncol.23(18), 4198–4214 (2005).
   PubMed Web of Science ®Google Scholar
• Smith TJ, Khatcheressian J, Lyman GH et al. Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J. Clin. Oncol.24(19), 3187–3205 (2006).
   PubMed Web of Science ®Google Scholar
• Carrato A, Paz-Ares Rodriguez L, Rescure A et al. Spanish Society of Medical Oncology consensus for the use of haematopoietic colony stimulating factors in cancer patients. Clin. Transl. Oncol.11, 446–454 (2009).
   Google Scholar
• Crawford J, Caserta C, Roila F. Hematopoietic growth factors: ESMO clinical practice guidelines for the applications. Ann. Oncol.21(Suppl. 5), v248–v251 (2010).
   PubMed Web of Science ®Google Scholar
• Aapro MS, Bohlius J, Cameron DA et al. 2010 update of EORTC guidelines for the use of granulocyte colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumors. Eur. J. Cancer47, 8–32 (2011).
   PubMed Web of Science ®Google Scholar
• Danova M, Rosti G, De Placido S, Bencardino K, Venturini M. Use of granulocyte colony-stimulating factor: a survey among Italian medical oncologists. Oncol. Rep.14(6), 1405–1412 (2005).
   Google Scholar
• Weycker D, Hackett J, Edelsberg JS, Oster G, Glass AG. Are shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization? Ann. Pharmacother.40(3), 402–407 (2006).
   PubMed Web of Science ®Google Scholar
• Hendler D, Rizel S, Yerushalmi R et al. Differente schedules of granulocyte growth factor support for patient with breast cancer receiving adjuvant dose-dense chemotherapy: a prospective non randomized study. Am. J. Clin. Oncol. PMID: 21217400 (2011) (Epub ahead of print).
   Google Scholar
• Falandry C, Campone H, Carton G, Guerin D, Freyer G. Trends in G-CSF use in 990 patients after EORTC and ASCO guidelines. Eur. J. Cancer46, 2389–2398 (2010).
   PubMed Web of Science ®Google Scholar
• Lingaratnam S, Slavin MA, Mileshkin L et al. An Australian survey of clinical practices in management of neutropenic fever in adult cancer patients 2009. J. Intern. Med.41, 110–120 (2011).
   Google Scholar
• Shinjo K, Takeshita A, Ohnishi K, Ohno R. Granulocyte colony-stimulating factor receptor at various differentiation stages of normal and leukemic hematopoietic cells. Leuk. Lymphoma25(1–2), 37–46 (1997).
   PubMed Web of Science ®Google Scholar
• Richards MK, Liu F, Iwasaki H, Akashi K, Link DC. Pivotal role of granulocyte colony-stimulating factor in the development of progenitors in the common myeloid pathway. Blood102(10), 3562–3568 (2003).
   PubMed Web of Science ®Google Scholar
• Engervall P, Lundahl J. Alterations in adhesion molecule (CD11b/CD18 and CD62L) expression on granulocytes after chemotherapy. Eur. J. Clin. Invest.28(11), 924–929 (1998).
   Google Scholar
• Terashi K, Oka M, Ohdo S et al. Close association between clearance of recombinant human granulocyte colony-stimulating factor (G-CSF) and G-CSF receptor on neutrophils in cancer patients. Antimicrob. Agents Chemother.43(1), 21–24 (1999).
   PubMed Web of Science ®Google Scholar
• Fink A, Kosecoff J, Chassin M, Brook RH. Consensus methods: characteristics and guidelines for use. Am. J. Public Health74(9), 979–983 (1984).
   PubMed Web of Science ®Google Scholar
• Murphy MK, Black NA, Lamping DL et al. Consensus development methods, and their use in clinical guideline development. Health Technol. Assess.2(3), i–iv 1–88 (1998).
   PubMedGoogle Scholar
• US Department of Health and Human Sciences PHS. Agency for Health Health Care Policy and Research. 115–127 (1992).
   Google Scholar
• Gafter-Gvili A, Fraser A, Paul M, Leibovici L. Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann. Intern. Med.142, 979–995 (2005).
   PubMed Web of Science ®Google Scholar
• Bokemeyer C, Honecker F, Wedding U, Spath-Schwalbe E, Lipp HP, Kolb G. Use of hematopoietic growth factors in elderly patients receiving cytotoxic chemotherapy. Onkologie25(1), 32–39 (2002).
   Google Scholar
• Lyman GH, Kuderer NM, Djulbegovic B. Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis. Am. J. Med.112(5), 406–411 (2002).
   PubMed Web of Science ®Google Scholar
• Sung L, Nathan PC, Alibhai SM, Tomlinson GA, Beyene J. Meta-analysis: effect of prophylactic hematopoietic colony-stimulating factors on mortality and outcomes of infection. Ann. Intern. Med.147(6), 400–411 (2007).
   PubMed Web of Science ®Google Scholar
• Kuderer NM, Dale DC, Crawford J, Lyman GH. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J. Clin. Oncol.25(21), 3158–3167 (2007).
   PubMed Web of Science ®Google Scholar
• Kuderer NM. Meta-analysis of randomized controlled trials of granulocyte colony-stimulating factor prophylaxis in adult cancer patients receiveng chemotherapy. Cancer Treat. Res.157, 127–143 (2011).
   Google Scholar
• Lyman GH, Kuderer NM, Crawford J et al. Prospective validation of a risk model for first cycle neutropenic complications in patients receiving cancer chemotherapy. J. Clin. Oncol.24(18S), 8561 (Abstract) (2006).
   Web of Science ®Google Scholar
• Ozer H, Armitage JO, Bennet CL et al. Update of recommendations for the use of haematopietic colony stimulating factors: evidenced-based, clinical practice guidelines. American Society of Clinical Oncology (ASCO) growth factors expert panel. J. Clin. Oncol.18, 3558–3585 (2000).
   PubMed Web of Science ®Google Scholar
• Vogel CL, Wojtukiewicz MZ, Carroll RR et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled Phase III study. J. Clin. Oncol.23(6), 1178–1184 (2005).
   PubMed Web of Science ®Google Scholar
• Timmer-Bonte JN, De Boo TM, Smit HJ et al. Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch randomized Phase III study. J. Clin. Oncol.23(31), 7974–7984 (2005).
   PubMed Web of Science ®Google Scholar
• Aapro M, Crawford J, Kamioner D. Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now? Supp. Care Cancer18, 529–541 (2010).
   PubMed Web of Science ®Google Scholar
• Chatta GS, Price TH, Allen RC, Dale DC. Effects of in vivo recombinant methionyl human granulocyte colony-stimulating factor on the neutrophil response and peripheral blood colony-forming cells in healthy young and elderly adult volunteers. Blood84(9), 2923–2929 (1994).
   PubMed Web of Science ®Google Scholar
• Crawford J, Kreisman H, Garewal H et al. The impact of filgrastim schedule variation on hematopoietic recovery post-chemotherapy. Ann. Oncol.8(11), 1117–1124 (1997).
   PubMed Web of Science ®Google Scholar
• Koumakis G, Vassilomanolakis M, Barbounis V et al. Optimal timing (preemptive versus supportive) of granulocyte colony-stimulating factor administration following high-dose cyclophosphamide. Oncology56(1), 28–35 (1999).
   PubMed Web of Science ®Google Scholar
• Holmes FA, O’Shaughnessy JA, Vukelja S et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J. Clin. Oncol.20(3), 727–731 (2002).
   PubMed Web of Science ®Google Scholar
• Green MD, Koelbl H, Baselga J et al. A randomized double-blind multicenter Phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann. Oncol.14(1), 29–35 (2003).
   PubMed Web of Science ®Google Scholar
• Von Minckwitz G, Kummel S, Du Bois A et al. Pegfilgrastim +/- ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study. Ann. Oncol.19(2), 292–298 (2008).
   PubMed Web of Science ®Google Scholar
• Morrison VA, Wong M, Hershman D, Campos LT, Ding B, Malin J. Observational study of the prevalence of febrile neutropenia in patients who received filgrastim or pegfilgrastim associated with 3–4 week chemotherapy regimens in community oncology practices. J. Manag. Care Pharm.13(4), 337–348 (2007).
   PubMed Web of Science ®Google Scholar
• Burstein HJ, Parker LM, Keshaviah A et al. Efficacy of pegfilgrastim and darbepoetin α as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy. J. Clin. Oncol.23(33), 8340–8347 (2005).
   PubMed Web of Science ®Google Scholar
• Hartmann LC, Tschetter LK, Habermann TM et al. Granulocyte colony-stimulating factor in severe chemotherapy-induced afebrile neutropenia. N. Engl. J. Med.336(25), 1776–1780 (1997).
   PubMed Web of Science ®Google Scholar
• Link BK, Budd GT, Scott S et al. Delivering adjuvant chemotherapy to women with early-stage breast carcinoma: current patterns of care. Cancer92(6), 1354–1367 (2001).
   PubMed Web of Science ®Google Scholar
• Lyman GH, Delgado DJ. Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma. Cancer98(11), 2402–2409 (2003).
   PubMed Web of Science ®Google Scholar
• Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N. Engl. J. Med.332(14), 901–906 (1995).
   PubMed Web of Science ®Google Scholar
• Papaldo P, Lopez M, Marolla P et al. Impact of five prophylactic filgrastim schedules on hematologic toxicity in early breast cancer patients treated with epirubicin and cyclophosphamide. J. Clin. Oncol.23(28), 6908–6918 (2005).
   PubMed Web of Science ®Google Scholar
• Leibovici L, Paul M, Cullen M et al. Antibiotic prophylaxis in neutropenic patients: new evidence, practical decisions. Cancer107(8), 1743–1751 (2006).
   PubMed Web of Science ®Google Scholar
• Imran H, Tleyjeh IM, Arndt CA et al. Fluoroquinolone prophylaxis in patients with neutropenia: a meta-analysis of randomized placebo-controlled trials. Eur. J. Clin. Microbiol. Infect. Dis.27(1), 53–63 (2008).
   PubMed Web of Science ®Google Scholar
• Gafter-Gvili A, Paul M, Fraser A, Leibovici L. Effect of quinolone prophylaxis in afebrile neutropenic patients on microbial resistance: systematic review and meta-analysis. J. Antimicrob. Chemother.59(1), 5–22 (2007).
   PubMed Web of Science ®Google Scholar
• Innes H, Lim SL, Hall A, Chan SY, Bhalla N, Marshall E. Management of febrile neutropenia in solid tumours and lymphomas using the Multinational Association for Supportive Care in Cancer (MASCC) risk index: feasibility and safety in routine clinical practice. Support. Care Cancer16(5), 485–491 (2008).
   PubMed Web of Science ®Google Scholar
• Klastersky J, Paesmans M, Georgala A et al. Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications. J. Clin. Oncol.24(25), 4129–4134 (2006).
   PubMed Web of Science ®Google Scholar
• Georgoulias V, Kouroussis C, Androulakis N et al. Front-line treatment of advanced non-small-cell lung cancer with docetaxel and gemcitabine: a multicenter Phase II trial. J. Clin. Oncol.17(3), 914–920 (1999).
   PubMed Web of Science ®Google Scholar
• Georgoulias V, Ardavanis A, Tsiafaki X et al. Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a Phase III randomized trial. J. Clin. Oncol.23(13), 2937–2945 (2005).
   PubMed Web of Science ®Google Scholar
• Riedel RF, Andrews C, Garst J et al. A Phase II trial of carboplatin/vinorelbine with pegfilgrastim support for the treatment of patients with advanced non-small cell lung cancer. J. Thorac. Oncol.2(6), 520–525 (2007).
   PubMed Web of Science ®Google Scholar
• De Wit R, Verweij J, Bontenbal M et al. Adverse effect on bone marrow protection of prechemotherapy granulocyte colony-stimulating factor support. J. Natl Cancer Inst.88(19), 1393–1398 (1996).
   Google Scholar
• Tjan-Heijnen VC, Biesma B, Festen J et al. Enhanced myelotoxicity due to granulocyte colony-stimulating factor administration until 48 hours before the next chemotherapy course in patients with small-cell lung carcinoma. J. Clin. Oncol.16(8), 2708–2714 (1998).
   PubMed Web of Science ®Google Scholar
• Frasci G, D’Aiuto G, Thomas R et al. Biweekly docetaxel-irinotecan treatment with filgrastim support is highly active in antracycline–paclitaxel-refractory breast cancer patients. Oncology68(4–6), 391–397 (2005).
   PubMed Web of Science ®Google Scholar
• Nistico C, Bria E, Agostara B et al. Weekly paclitaxel, 5-fluorouracil and folinic acid with granulocyte colony-stimulating factor support in metastatic breast cancer patients: a Phase II study. Anticancer Drugs17(3), 345–351 (2006).
   Google Scholar
• Nistico C, De Matteis A, Rossi E et al. Primary chemotherapy with epirubicin and vinorelbine in women with locally advanced breast cancer. Anticancer Res.25(2B), 1343–1348 (2005).
   Google Scholar
• Makatsoris T, Papakostas P, Kalofonos HP et al. Intensive weekly chemotherapy with docetaxel, epirubicin and carboplatin with G-CSF support in patients with advanced gastric cancer: a Hellenic Cooperative Oncology Group (HeCOG) Phase II study. Med. Oncol.24(3), 301–307 (2007).
   Google Scholar
• Benasso M, Lionetto R, Corvo R, Ponzanelli A, Vitale V, Rosso R. Impact of the treating institution on the survival of patients with head and neck cancer treated with concomitant alternating chemotherapy and radiation. Eur. J. Cancer39(13), 1895–1898 (2003).
   Google Scholar
• Sheikh H, Colaco R, Lorigan P et al. Use of G-CSF during concurrent chemotherapy and thoracic radiotherapy in patients with limited-stage small cell lung cancer: safety data from a Phase II trial. Lung Cancer DOI: 10.1016/j.lungcan.2011.01.020 (2011) (Epub ahead of print).
   Google Scholar
• Kelly S, Wheatley D. Prevention of febrile neutropenia: use of granulocyte colony-stimulating factors. Br. J. Cancer101, 6–10 (2009).
   PubMed Web of Science ®Google Scholar
• Advani SH, Achreckar S, Thomas D, Krishnankutty B. Granulocyte colony-stimulating factor (filgrastim) in chemotherapy-induced febrile neutropenia. Indian J. Med. Paed. Oncol.31, 79–82 (2010).
   Google Scholar
• Saloustros E, Tryfonidis K, Georgoulias V. Prophylactic and therapeutic strategies in chemotherapy-induced neutropenia. Exp. Opin. Pharmacother.12(6), 851–863 (2011).
   PubMed Web of Science ®Google Scholar
• Gunzer K, Clarisse B, Lheureux S, Delcambre C, Joly F. Contibution of glycosylated recombinant human granulocyte colony-stimulating factor (lenograstim) use in current cancer treatment: review of clinical data. Exp. Opin. Biol. Ther.10, 615–630 (2010).
   PubMed Web of Science ®Google Scholar
• Orciuolo E, Buda G, Marturano E et al. Lenograstim reduces the incidence of febrile episodes, when compared with filgrastim, in multiple myeloma patients undergoing stem cell mobilization. Leuk. Res.35(7), 899–903 (2011).
   PubMed Web of Science ®Google Scholar
• Weycker D, Malin J, Barron R, Edelsberg J, Kartashov A, Oster G. Comparative effectiveness of filgrastim, pegfilgrastim and sargramostim as prophylaxis against hospitalization for neutropenic complications in patients with cancer receiving chemotherapy. Am. J. Clin. Oncol. PMID: 21378538 (2011) (Epub ahead of print).
   Google Scholar
• Tan H, Tomic K, Hurley D, Daniel G, Barron R, Malin J. Comparative effectiveness of colony stimulating factors for febrile neutropenia: a retrospective study. Curr. Med. Res. Opin.27, 79–86 (2011).
   PubMed Web of Science ®Google Scholar
• Danova M, Rosti G, Doan QV. Cost–effectiveness of pegfilgrastim versus six days of filgrastim for preventing febrile neutropenia in breast cancer patients. Tumori95(2), 219–226 (2009).
   PubMed Web of Science ®Google Scholar
• Liu Z, Doan QV, Malin J, Leonard R. The economic value of primary prophylaxis using pegfilgrastim compared with filgrastim in patients with breast cancer in the UK. Appl. Health Econ. Health Policy7, 193–205 (2009).
   PubMedGoogle Scholar
• Weycker D, Barron RL. Comparison of hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-induced neutropenia. Cancer116, 3073–3074 (2010).
   Google Scholar
• Sullivan SD, Ramsey SD, Blough DK, McDermott CL, Clarke L, McCune JS. Health care use and primary prophylaxis with colony stimulating factors. Value Health14, 247–252 (2011).
   PubMedGoogle Scholar
• Mellstedt H, Niederwiser D, Ludwig H. The challenge of biosimilars. Ann. Oncol.19, 411–419 (2008).
   PubMed Web of Science ®Google Scholar
• Gascon P, Fuhr U, Sorgel F et al. Development of a new G-CSF product based on biosimilarity assessment. Ann. Oncol.21, 1419–1429 (2010).
   PubMed Web of Science ®Google Scholar
• Skrlin A, Radic I, Vuletic M et al. Comparison of the physico-chemical properties of a biosimilar filgrastim with those of reference filgrastim. Biologicals38, 557–566 (2010).
   PubMed Web of Science ®Google Scholar